Biotech | August 10, 2021
Eagle Pharmaceuticals announces licensing agreement for Landiolol
Deal signed with AOP Orphan for US commercial rights
Deal signed with AOP Orphan for US commercial rights
A veteran in cell therapy and oncology commercialisation
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
The drug is indicated for mild and transient episodes of heart block
Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
This work has been published in the journal ‘ACS applied materials and interface’
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
Deal for 100 million doses with additional 100 million through 2023
It posted net loss of Rs.(2429.81) crores for the period ended June 30, 2020.
Subscribe To Our Newsletter & Stay Updated
